Literature DB >> 27838151

Use of concurrent chemoradiation in advanced staged (T4) laryngeal cancer.

Cameron C Wick1, Rod P Rezaee2, Tammy Wang2, Andrea M Garcia-Jarchow3, Chad A Zender2, Michael Gibson4, Min Yao5, Pierre Lavertu6.   

Abstract

HYPOTHESIS: Patients with advanced laryngeal cancer sometimes desire organ preservation protocols even if it portends a worse outcome.
BACKGROUND: To assess outcomes of patients with T4 laryngeal cancer treated with chemoradiation therapy.
METHODS: Case series with chart review at a tertiary university hospital. Twenty-four patients with T4 laryngeal cancer all declined total laryngectomy with adjuvant radiation as the primary treatment modality and alternatively received concurrent chemoradiation therapy. The primary outcome was overall survival. Secondary outcomes were rates of tracheotomy dependence, gastric tube dependence, and need for salvage laryngectomy.
RESULTS: All patients had T4 laryngeal disease, 71% had cartilage invasion and 59% had regional metastasis to the neck. Kaplan-Meier analysis determined 2-year and 5-year overall survival to be 64% and 59% respectively. The locoregional recurrence rate was 25%. The distant metastasis rate was 21%. The rate of salvage laryngectomy was 17%, which occurred at a mean of 56.5months after the original diagnosis. The rate of tracheotomy dependence was 33% while gastric tube dependence was 25%.
CONCLUSION: Advanced T4 laryngeal cancer, particularly with cartilage invasion, remains a surgical disease best treated with total laryngectomy and adjuvant radiation. This data may help guide patients and practitioners considering concurrent chemoradiation therapy for definitive treatment of advanced laryngeal cancer.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27838151     DOI: 10.1016/j.amjoto.2016.10.001

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  3 in total

1.  Effect of voice rehabilitation training on the patients with laryngeal cancer after radiotherapy.

Authors:  Mei-Jia Zhang; Ji-Wei Mu; Xiang-Ru Chen; Xin Zhang; Chong Feng
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 2.  Review of recent treatment trends of laryngeal cancer in Poland: a population-based study.

Authors:  Anna Rzepakowska; Michał Żurek; Kazimierz Niemczyk
Journal:  BMJ Open       Date:  2021-04-30       Impact factor: 2.692

3.  The Expression and Therapeutic Potential of Checkpoint Kinase 2 in Laryngeal Squamous Cell Carcinoma.

Authors:  Ying Tian; Yan Wang; Shan Xu; Chao Guan; Qingfu Zhang; Wei Li
Journal:  Drug Des Devel Ther       Date:  2020-07-06       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.